AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD) – UC and ...

Plug Power, Lucid Group, and Boeing stocks have all suffered business reversals, but many investors hope they will rebound.

AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer ...

Shareholders are getting serious about sustainability. by Robert G. Eccles and Svetlana Klimenko Most corporate leaders understand that businesses have a key role to play in tackling urgent challenges ...